Heart Failure
Conditions
Keywords
obesity, sodium, DASH diet, hypertension, vascular stiffness, diastolic function
Brief summary
Tens of thousands of Veterans have heart failure with preserved ejection fraction (HFpEF), and suffer poor quality of life, frequent hospitalizations, and high death rates. Older Veterans and those with high blood pressure, obesity, and the metabolic syndrome (abnormal cholesterol and resistance to insulin's effects) are particularly at risk for HFpEF. However, it is not clear why only some Veterans in this risk group eventually develop HFpEF. Extensive information from experimental animal models and some human studies suggests that dietary patterns in vulnerable 'salt-sensitive' people could contribute to the risk for HFpEF. Reducing salt intake and increasing overall dietary quality in at-risk Veterans could prevent heart and blood vessel damage that ultimately leads to HFpEF. Reducing the development of HFpEF, which currently has no definitive treatment, is highly relevant to the VA's mission to emphasize prevention of disease and population health.
Detailed description
COVID-19 in-person visit hold has been removed- screening and actively enrolling. We are not currently performing sublingual darkfield microscopy because of the need for close face-to-face contact with an open-mouthed patient for several minutes in the setting of COVID-19 pandemic. Patients with heart failure (HF) account for over 1,200,000 VA outpatient visits per year, and HF remains the most common cause for hospital admission in the VA. Approximately 1/3 of Veterans with HF have 'preserved' ejection fraction (HFpEF), or relatively normal contractile function of the heart; such patients suffer functional decline and poor quality of life, and half die within 5 years after diagnosis. Risk factors for developing HFpEF are more common in Veterans than the general population, and the burden of HFpEF to the VA system will rise in the years ahead as these Veterans age. Preventive efforts are critical, but are hampered by gaps in knowledge related to HFpEF pathophysiology. The long term goal of this proposal is to prevent the onset of HFpEF in at-risk Veterans. Hypertension (HTN) confers the highest population-attributable risk for HFpEF, particularly when accompanied by the metabolic syndrome, a constellation of obesity, insulin resistance, and dyslipidemia. Animal models of HTN and metabolic syndrome develop HFpEF due to microvascular oxidative stress and inflammation induced by high sodium intake. Recent data from cardiac biopsies confirm similar mechanisms in human HFpEF. Dietary sodium restriction is widely recommended to prevent HTN-associated heart disease in humans, but this advice is now controversial. Few studies have examined how individual differences in response to sodium intake affect risk. Salt-sensitive persons have blood pressure (BP) that changes in parallel with sodium intake, and commonly develop cardiovascular abnormalities associated with HFpEF. The overall objective of this proposal is to evaluate salt-sensitivity as a novel, diet-responsive risk factor for incident HFpEF in Veterans with HTN and metabolic syndrome. The central hypothesis is that the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating pattern will improve cardiovascular functional and structural risk factors for HFpEF in Veterans with the salt-sensitive phenotype. Guided by findings in experimental models, cohort studies, and strong preliminary evidence from the investigators' research group, this hypothesis will be tested in a two-phase study and by pursuing three specific aims: 1) Determine effects of DASH/SRD on functional and structural cardiovascular HFpEF risk factors in salt-sensitive vs. salt-resistant Veterans, 2) measure the effect of an electronically-delivered tailored-messaging intervention on DASH/SRD adherence, and 3) determine effects of DASH/SRD intervention and adoption on microvascular function and assess the endothelial glycocalyx as a biomarker of cardiovascular response to DASH/SRD. Phase 1 of the study is a sequential comparison of DASH/SRD vs. control diet for two weeks each, and Phase 2 a 6-month extension to promote DASH/SRD adherence. The salt-sensitive phenotype will be defined by between-diet changes in 24-hour mean BP during Phase 1. In Phase 2, the efficacy of motivational interviewing-based counseling and the Women's and Men's Hypertension Experiences and Emerging Lifestyles Intervention (WHEELS-I), a tailored messaging program, to sustain DASH/SRD adherence, will be compared. Echocardiography and arterial tonometry will be used to assess HFpEF-related cardiovascular parameters during short- and longer-term dietary modification and their interaction with salt-sensitivity. In vivo microscopy and novel blood testing will assess microvascular function and the integrity of the endothelial glycocalyx, a blood vessel lining that is sodium-responsive and may mediate the adverse effects of salt-sensitivity. This proposal is innovative because it represents the first study to examine salt-sensitivity as a factor promoting HFpEF in Veterans with HTN and metabolic syndrome, the highest risk group for incident HFpEF. Moreover, it aims to link microvascular dysfunction, an important pathway in human HFpEF, with endothelial glycocalyx damage, a potential biomarker for sodium-mediated vascular risk. The proposed research is significant because it will vertically advance the investigators' understanding of how dietary factors contribute to the pathophysiology of HFpEF, a major and growing health threat to Veterans.
Interventions
All participants will receive motivational interviewing (MI) based counseling. Participants in the MI + WHEELS-I arm will also receive the WHEELS-I electronically-delivered tailored messaging.
Sponsors
Study design
Intervention model description
Phase 1 of study: sequential design, 14 days each of usual diet followed by 14 days of sodium-restricted DASH diet Phase 2 of study: randomized assignment, 6 months of motivational interviewing vs. motivational interviewing plus mobile application-based promotion of dietary adherence
Eligibility
Inclusion criteria
* Veterans aged 45 years with HTN * here defined as screening systolic BP 130 and/or diastolic BP 85 mmHg, or current use of anti-hypertensive drugs * and metabolic syndrome * body mass index 30 kg/m2 and/or waist circumference \>94 cm * Participants must also be willing to participate in the WHEELS-I program by using a smartphone application or email
Exclusion criteria
* On-treatment systolic BP of \>160 mmHg at screening visit * previous history of HF * left ventricular ejection fraction \<50% * moderate or severe valvular heart disease * myocardial infarction or stroke within the prior 6 months * chronic kidney disease with estimated glomerular filtration rate \<45 ml/min/ 1.73m2 * unoperated aortic aneurysm for which surgery is indicated, prior hyperkalemia requiring urgent treatment * hemoglobin \<9 gm/dL * investigator-determined factors: severe pulmonary disease, e.g.: * oxygen-requiring * hepatic disease, e.g.: * cirrhosis * severely uncontrolled diabetes (hemoglobin A1c \>10%) * active cancer other than non-melanoma skin or low-risk prostate cancer * other comorbidity with expected survival \<12 months * active alcohol/illicit substance abuse * and/or a history of persistent nonadherence to treatment * Veterans involved in another study (unless it is survey-only and the other investigator will allow us to invite the person in a survey-only study to consider our study)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Carotid-femoral Pulse Wave Velocity | Phase 1 of study, change between week 2 and week 4 | Phase 1 primary hypothesis: greater reduction in carotid-femoral pulse wave velocity with DASH diet in individuals with salt-sensitive blood pressure Change in velocity of pulse wave traveling between carotid and femoral artery; validated measure of arterial stiffness |
| Left Ventricular Mass Index | Phase 2 of study, change from baseline to 6 months | Left ventricular mass indexed to body surface area. Larger/greater left ventricular mass index is associated with increased long-term risk of cardiovascular events, including the development of heart failure. Normal values for men are 49-115 g/m² and for women 43-95 g/m² |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Global Longitudinal Left Ventricular Strain | Phase 1 of study, change between week 2 to week 4 | Global longitudinal left ventricular strain (GLS), a sensitive measure of ventricular systolic function GLS is calculated by dividing the reduction in length of a myocardial (heart) segment from the end of diastole (maximum relaxation) to the end of systole (maximum contraction) by the segment's original length at end-diastole (i.e. change in length/original length). GLS is averaged across six myocardial segments, is expressed in a percentage, and is negative by convention since cardiac segment length decreases during systole. The more negative/greater magnitude, the better the GLS. Normal GLS is -18% to -22%. Low GLS is associated with long-term increased risk of cardiovascular events, including the development of heart failure. |
| Carotid-femoral Pulse Wave Velocity | Phase 2 of study, change from baseline to 6 months | Velocity of pulse wave traveling between carotid and femoral artery; validated measure of arterial stiffness |
Other
| Measure | Time frame | Description |
|---|---|---|
| Clinic Systolic Blood Pressure | Phase 2 of study, change from baseline to 6 months | Change in systolic blood pressure obtained in clinic with automated brachial cuff |
| Clinic Diastolic Blood Pressure | Phase 2 of study, change from baseline to 6 months | — |
| Salt-sensitivity Phenotype | Phase 1 of study, change between week 2 and week 4 | Salt-sensitive blood pressure means that blood pressure changes more than 'normal' when dietary sodium intake changes, i.e. increases or decreases in parallel with sodium intake. Having a salt-sensitive blood pressure pattern is an independent long-term risk factor for cardiovascular events. Variable testing approaches, blood pressure thresholds, and methods of blood pressure measurement have been proposed in the literature to define blood pressure salt-sensitivity. In this study, we report salt-sensitive vs. non salt-sensitive as a binary variable. Change in 24-hour mean blood pressure of \>= 4 mmHg between the ad-lib and home-delivered meal periods of Phase 1 defines the salt-sensitive blood pressure phenotype |
| Urine Sodium and Potassium Ratios | Phase 2 of study, change from baseline to 6 months | Unitless ratio of urine sodium (in mmol) divided by urine potassium (in mmol), measured from spot samples taken from 24-hour urine samples. |
| Triglycerides | Phase 2 of study, change from baseline to 6 months | Serum triglyceride changes during dietary intervention |
| 24-hour Urinary Sodium Excretion | Phase 2 of study, change from baseline to 6 months | Measure of daily dietary sodium intake |
| Sodium-restricted DASH Diet Adherence by Food Frequency Questionnaire (FFQ) | Phase 2 of study, change from baseline to 6 months | Sodium-restricted DASH diet score on FFQ, measured by quintiles of intake in 8 dietary domains as compared with age- and sex-matched norms from NHANES national US survey data. Score ranges 8-40 points, with higher scores indicating greater adherence |
| Sodium-restricted DASH Diet Adherence | Phase 2 of study, change from baseline to 6 months | Analysis of 3-day food diaries by a Registered Dietitian, utilizing the Nutrition Data System for Research. DASH diet adherence score based on proportion of recommended daily intake in 9 domains, score ranges 0-9 points with higher scores indicating greater adherence |
Countries
United States
Participant flow
Pre-assignment details
Phase 1: Screening visit: Follow baseline diet for 2 weeks Excluded if patient couldn't wean from renin-angiotensin-aldosterone system (RAAS) inhibitors and diuretics without complications 2-week visit: follow DASH-SRD diet for 2 weeks 4-week visit: randomized into Arm 1 or 2 and begin phase II of study.
Participants by arm
| Arm | Count |
|---|---|
| Phase 1: 2-week Diet As Usual Then 2 Weeks of DASH/SRD Diet This arm includes all participants who started Phase 1 of the study. Phase 1 took place prior to randomization into either the Motivational Interviewing or Motivational Interviewing + WHEELS-I arm. | 71 |
| Motivational Interviewing + WHEELS-I In addition to motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan., participants in this arm will also receive an electronically-delivered tailored messaging intervention called Women's and Men's Hypertension Experiences and Emerging Lifestyle Intervention (WHEELS-I). Randomization will occur after phase 1 of the study which includes 2 weeks of an ad lib diet followed by 2 weeks of prepared pre-packaged DASH/SRD meals. | 28 |
| Motivational Interviewing Participants in this arm will receive motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan. Randomization will occur after phase 1 of the study which includes 2 weeks of an ad lib diet followed by 2 weeks of prepared pre-packaged DASH/SRD meals. | 38 |
| Total | 137 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Phase 1 - 4 Weeks | Withdrawal by Subject | 5 | 0 | 0 |
| Phase 2 - 6 Months | Withdrawal by Subject | 0 | 3 | 2 |
Baseline characteristics
| Characteristic | Total | Phase 1: 2-week Diet As Usual Then 2 Weeks of DASH/SRD Diet | Motivational Interviewing + WHEELS-I | Motivational Interviewing |
|---|---|---|---|---|
| Age, Continuous Phase 1 | 66 years STANDARD_DEVIATION 8 | 66 years STANDARD_DEVIATION 8 | — | — |
| Age, Continuous Phase 2 | 66 years STANDARD_DEVIATION 8 | — | 64 years STANDARD_DEVIATION 9 | 67 years STANDARD_DEVIATION 8 |
| BMI Phase 1 | 34.4 kg/m^2 STANDARD_DEVIATION 5.1 | 34.4 kg/m^2 STANDARD_DEVIATION 5.1 | — | — |
| BMI Phase 2 | 34.5 kg/m^2 STANDARD_DEVIATION 5.1 | — | 34.7 kg/m^2 STANDARD_DEVIATION 4.7 | 34.4 kg/m^2 STANDARD_DEVIATION 5.5 |
| Diastolic Blood Pressure Phase 1 | 72 mmHg STANDARD_DEVIATION 11 | 72 mmHg STANDARD_DEVIATION 11 | — | — |
| Diastolic Blood Pressure Phase 2 | 73 mmHg STANDARD_DEVIATION 11 | — | 74 mmHg STANDARD_DEVIATION 11 | 72 mmHg STANDARD_DEVIATION 11 |
| Ethnicity (NIH/OMB) Phase 1 Hispanic or Latino | 4 Participants | 4 Participants | — | — |
| Ethnicity (NIH/OMB) Phase 1 Not Hispanic or Latino | 63 Participants | 63 Participants | — | — |
| Ethnicity (NIH/OMB) Phase 1 Unknown or Not Reported | 4 Participants | 4 Participants | — | — |
| Ethnicity (NIH/OMB) Phase 2 Hispanic or Latino | 3 Participants | — | 3 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Phase 2 Not Hispanic or Latino | 59 Participants | — | 23 Participants | 36 Participants |
| Ethnicity (NIH/OMB) Phase 2 Unknown or Not Reported | 4 Participants | — | 2 Participants | 2 Participants |
| HDL Cholesterol Phase 1 | 45 mg/dL STANDARD_DEVIATION 10 | 45 mg/dL STANDARD_DEVIATION 10 | — | — |
| HDL Cholesterol Phase 2 | 45 mg/dL STANDARD_DEVIATION 10 | — | 43 mg/dL STANDARD_DEVIATION 9 | 46 mg/dL STANDARD_DEVIATION 11 |
| Hemoglobin A1c Phase 1 | 6.2 % STANDARD_DEVIATION 1.1 | 6.2 % STANDARD_DEVIATION 1.1 | — | — |
| Hemoglobin A1c Phase 2 | 6.3 % STANDARD_DEVIATION 1.1 | — | 6.3 % STANDARD_DEVIATION 1 | 6.3 % STANDARD_DEVIATION 1.1 |
| Hip Circumference Phase 1 | 117 cm STANDARD_DEVIATION 15 | 117 cm STANDARD_DEVIATION 15 | — | — |
| Hip Circumference Phase 2 | 117 cm STANDARD_DEVIATION 15 | — | 118 cm STANDARD_DEVIATION 11 | 116 cm STANDARD_DEVIATION 17 |
| Race (NIH/OMB) Phase 1 American Indian or Alaska Native | 0 Participants | 0 Participants | — | — |
| Race (NIH/OMB) Phase 1 Asian | 1 Participants | 1 Participants | — | — |
| Race (NIH/OMB) Phase 1 Black or African American | 10 Participants | 10 Participants | — | — |
| Race (NIH/OMB) Phase 1 More than one race | 0 Participants | 0 Participants | — | — |
| Race (NIH/OMB) Phase 1 Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | — | — |
| Race (NIH/OMB) Phase 1 Unknown or Not Reported | 3 Participants | 3 Participants | — | — |
| Race (NIH/OMB) Phase 1 White | 57 Participants | 57 Participants | — | — |
| Race (NIH/OMB) Phase 2 American Indian or Alaska Native | 0 Participants | — | 0 Participants | 0 Participants |
| Race (NIH/OMB) Phase 2 Asian | 1 Participants | — | 1 Participants | 0 Participants |
| Race (NIH/OMB) Phase 2 Black or African American | 10 Participants | — | 2 Participants | 8 Participants |
| Race (NIH/OMB) Phase 2 More than one race | 0 Participants | — | 0 Participants | 0 Participants |
| Race (NIH/OMB) Phase 2 Native Hawaiian or Other Pacific Islander | 0 Participants | — | 0 Participants | 0 Participants |
| Race (NIH/OMB) Phase 2 Unknown or Not Reported | 3 Participants | — | 2 Participants | 1 Participants |
| Race (NIH/OMB) Phase 2 White | 52 Participants | — | 23 Participants | 29 Participants |
| Sex: Female, Male Phase 1 Female | 11 Participants | 11 Participants | — | — |
| Sex: Female, Male Phase 1 Male | 60 Participants | 60 Participants | — | — |
| Sex: Female, Male Phase 2 Female | 10 Participants | — | 3 Participants | 7 Participants |
| Sex: Female, Male Phase 2 Male | 56 Participants | — | 25 Participants | 31 Participants |
| Systolic Blood Pressure Phase 1 | 133 mmHg STANDARD_DEVIATION 15 | 133 mmHg STANDARD_DEVIATION 15 | — | — |
| Systolic Blood Pressure Phase 2 | 134 mmHg STANDARD_DEVIATION 15 | — | 136 mmHg STANDARD_DEVIATION 14 | 132 mmHg STANDARD_DEVIATION 16 |
| Triglycerides Phase 1 | 163 mg/dL STANDARD_DEVIATION 107 | 163 mg/dL STANDARD_DEVIATION 107 | — | — |
| Triglycerides Phase 2 | 157 mg/dL STANDARD_DEVIATION 105 | — | 157 mg/dL STANDARD_DEVIATION 54 | 157 mg/dL STANDARD_DEVIATION 131 |
| Waist Circumference Phase 1 | 116 cm STANDARD_DEVIATION 14 | 116 cm STANDARD_DEVIATION 14 | — | — |
| Waist Circumference Phase 2 | 116 cm STANDARD_DEVIATION 14 | — | 117 cm STANDARD_DEVIATION 9 | 116 cm STANDARD_DEVIATION 17 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 28 | 0 / 38 |
| other Total, other adverse events | 0 / 28 | 0 / 38 |
| serious Total, serious adverse events | 1 / 28 | 2 / 38 |
Outcome results
Carotid-femoral Pulse Wave Velocity
Phase 1 primary hypothesis: greater reduction in carotid-femoral pulse wave velocity with DASH diet in individuals with salt-sensitive blood pressure Change in velocity of pulse wave traveling between carotid and femoral artery; validated measure of arterial stiffness
Time frame: Phase 1 of study, change between week 2 and week 4
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Salt-sensitive Participants | Carotid-femoral Pulse Wave Velocity | -0.3 m/s | Standard Deviation 1.6 |
| Non Salt-sensitive Participants | Carotid-femoral Pulse Wave Velocity | 0.4 m/s | Standard Deviation 3 |
Left Ventricular Mass Index
Left ventricular mass indexed to body surface area. Larger/greater left ventricular mass index is associated with increased long-term risk of cardiovascular events, including the development of heart failure. Normal values for men are 49-115 g/m² and for women 43-95 g/m²
Time frame: Phase 2 of study, change from baseline to 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Salt-sensitive Participants | Left Ventricular Mass Index | -3.3 g/m2 | Standard Deviation 15.5 |
| Non Salt-sensitive Participants | Left Ventricular Mass Index | -1.7 g/m2 | Standard Deviation 12.2 |
Carotid-femoral Pulse Wave Velocity
Velocity of pulse wave traveling between carotid and femoral artery; validated measure of arterial stiffness
Time frame: Phase 2 of study, change from baseline to 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Salt-sensitive Participants | Carotid-femoral Pulse Wave Velocity | 1.1 m/s | Standard Deviation 1.5 |
| Non Salt-sensitive Participants | Carotid-femoral Pulse Wave Velocity | 0.3 m/s | Standard Deviation 1.9 |
Global Longitudinal Left Ventricular Strain
Global longitudinal left ventricular strain (GLS), a sensitive measure of ventricular systolic function GLS is calculated by dividing the reduction in length of a myocardial (heart) segment from the end of diastole (maximum relaxation) to the end of systole (maximum contraction) by the segment's original length at end-diastole (i.e. change in length/original length). GLS is averaged across six myocardial segments, is expressed in a percentage, and is negative by convention since cardiac segment length decreases during systole. The more negative/greater magnitude, the better the GLS. Normal GLS is -18% to -22%. Low GLS is associated with long-term increased risk of cardiovascular events, including the development of heart failure.
Time frame: Phase 1 of study, change between week 2 to week 4
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Salt-sensitive Participants | Global Longitudinal Left Ventricular Strain | -0.2 ratio | Standard Deviation 2.5 |
| Non Salt-sensitive Participants | Global Longitudinal Left Ventricular Strain | -0.5 ratio | Standard Deviation 2 |
24-hour Urinary Sodium Excretion
Measure of daily dietary sodium intake
Time frame: Phase 2 of study, change from baseline to 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Salt-sensitive Participants | 24-hour Urinary Sodium Excretion | -456 mg/24h | Standard Deviation 2077 |
| Non Salt-sensitive Participants | 24-hour Urinary Sodium Excretion | -204 mg/24h | Standard Deviation 1721 |
Clinic Diastolic Blood Pressure
Time frame: Phase 2 of study, change from baseline to 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Salt-sensitive Participants | Clinic Diastolic Blood Pressure | -3.2 mmHg | Standard Deviation 10.7 |
| Non Salt-sensitive Participants | Clinic Diastolic Blood Pressure | -3.5 mmHg | Standard Deviation 10.8 |
Clinic Systolic Blood Pressure
Change in systolic blood pressure obtained in clinic with automated brachial cuff
Time frame: Phase 2 of study, change from baseline to 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Salt-sensitive Participants | Clinic Systolic Blood Pressure | -5.4 mmHg | Standard Deviation 12.9 |
| Non Salt-sensitive Participants | Clinic Systolic Blood Pressure | -4.1 mmHg | Standard Deviation 15.8 |
Salt-sensitivity Phenotype
Salt-sensitive blood pressure means that blood pressure changes more than 'normal' when dietary sodium intake changes, i.e. increases or decreases in parallel with sodium intake. Having a salt-sensitive blood pressure pattern is an independent long-term risk factor for cardiovascular events. Variable testing approaches, blood pressure thresholds, and methods of blood pressure measurement have been proposed in the literature to define blood pressure salt-sensitivity. In this study, we report salt-sensitive vs. non salt-sensitive as a binary variable. Change in 24-hour mean blood pressure of \>= 4 mmHg between the ad-lib and home-delivered meal periods of Phase 1 defines the salt-sensitive blood pressure phenotype
Time frame: Phase 1 of study, change between week 2 and week 4
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Salt-sensitive Participants | Salt-sensitivity Phenotype | 9 Participants |
| Non Salt-sensitive Participants | Salt-sensitivity Phenotype | 22 Participants |
Sodium-restricted DASH Diet Adherence
Analysis of 3-day food diaries by a Registered Dietitian, utilizing the Nutrition Data System for Research. DASH diet adherence score based on proportion of recommended daily intake in 9 domains, score ranges 0-9 points with higher scores indicating greater adherence
Time frame: Phase 2 of study, change from baseline to 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Salt-sensitive Participants | Sodium-restricted DASH Diet Adherence | 0.3 points | Standard Deviation 1.3 |
| Non Salt-sensitive Participants | Sodium-restricted DASH Diet Adherence | 0.6 points | Standard Deviation 1.6 |
Sodium-restricted DASH Diet Adherence by Food Frequency Questionnaire (FFQ)
Sodium-restricted DASH diet score on FFQ, measured by quintiles of intake in 8 dietary domains as compared with age- and sex-matched norms from NHANES national US survey data. Score ranges 8-40 points, with higher scores indicating greater adherence
Time frame: Phase 2 of study, change from baseline to 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Salt-sensitive Participants | Sodium-restricted DASH Diet Adherence by Food Frequency Questionnaire (FFQ) | 1.5 points | Standard Deviation 3.1 |
| Non Salt-sensitive Participants | Sodium-restricted DASH Diet Adherence by Food Frequency Questionnaire (FFQ) | 1.4 points | Standard Deviation 2.8 |
Triglycerides
Serum triglyceride changes during dietary intervention
Time frame: Phase 2 of study, change from baseline to 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Salt-sensitive Participants | Triglycerides | 41 mg/dL | Standard Deviation 39 |
| Non Salt-sensitive Participants | Triglycerides | 39 mg/dL | Standard Deviation 127 |
Urine Sodium and Potassium Ratios
Unitless ratio of urine sodium (in mmol) divided by urine potassium (in mmol), measured from spot samples taken from 24-hour urine samples.
Time frame: Phase 2 of study, change from baseline to 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Salt-sensitive Participants | Urine Sodium and Potassium Ratios | -1.2 ratio | Standard Deviation 1.1 |
| Non Salt-sensitive Participants | Urine Sodium and Potassium Ratios | -1.2 ratio | Standard Deviation 1.2 |